Kalbe Farma Tbk PT
IDX:KLBF
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 275
1 750
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Kalbe Farma Tbk PT
Kalbe Farma Tbk PT
Total Current Liabilities
Kalbe Farma Tbk PT
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Total Current Liabilities
Rp4.1T
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Total Current Liabilities
Rp2.8T
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Total Current Liabilities
Rp610.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Total Current Liabilities
Rp2.2T
|
CAGR 3-Years
7%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Total Current Liabilities
Rp2.3T
|
CAGR 3-Years
172%
|
CAGR 5-Years
141%
|
CAGR 10-Years
49%
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Total Current Liabilities
Rp7.8T
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
24%
|
|
Kalbe Farma Tbk PT
Glance View
Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.
See Also
What is Kalbe Farma Tbk PT's Total Current Liabilities?
Total Current Liabilities
4.1T
IDR
Based on the financial report for Sep 30, 2024, Kalbe Farma Tbk PT's Total Current Liabilities amounts to 4.1T IDR.
What is Kalbe Farma Tbk PT's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
5%
Over the last year, the Total Current Liabilities growth was -2%. The average annual Total Current Liabilities growth rates for Kalbe Farma Tbk PT have been 7% over the past three years , 10% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
